Prestige Consumer Healthcare (PBH) Total Current Liabilities (2011 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Total Current Liabilities came in at $139.6 million in Q4 2025, up 36.09% year-on-year from $102.5 million in Q4 2024, and up 3.68% quarter-over-quarter from $134.6 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Total Current Liabilities (2011 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Total Current Liabilities history runs 15 years deep, the most recent figure standing at $139.6 million for Q4 2025.
- On a quarterly basis, Total Current Liabilities rose 36.09% year-over-year to $139.6 million in Q4 2025; TTM through Dec 2025 was $139.6 million, a 36.09% increase from a year earlier, with the FY2025 full-year figure at $106.6 million, down 8.91% from the prior year.
- Total Current Liabilities rose to $139.6 million in Q4 2025 per PBH's latest filing, from $134.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $160.7 million in Q1 2023 and bottomed at $102.5 million in Q4 2024.
- The 5-year median for Total Current Liabilities is $132.2 million (2023), against an average of $131.9 million.
- Across the five-year window, Total Current Liabilities declined 27.17% in 2024 and surged 36.09% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $135.1 million in 2021, then increased by 18.54% to $160.2 million in 2022, then retreated by 20.44% to $127.4 million in 2023, then fell by 19.53% to $102.5 million in 2024, then jumped by 36.09% to $139.6 million in 2025.
- Per Business Quant, the three latest PBH Total Current Liabilities figures stand at $139.6 million (Q4 2025), $134.6 million (Q3 2025), and $109.7 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | 139.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 139.56 Mn |
| Sep 30, 2025 | 134.60 Mn |
| Jun 30, 2025 | 109.67 Mn |
| Mar 31, 2025 | 106.62 Mn |
| Dec 31, 2024 | 102.55 Mn |
| Sep 30, 2024 | 106.91 Mn |
| Jun 30, 2024 | 114.12 Mn |
| Mar 31, 2024 | 117.05 Mn |
| Dec 31, 2023 | 127.44 Mn |
| Sep 30, 2023 | 129.70 Mn |
| Jun 30, 2023 | 147.27 Mn |
| Mar 31, 2023 | 160.72 Mn |
| Dec 31, 2022 | 160.18 Mn |
| Sep 30, 2022 | 152.31 Mn |
| Jun 30, 2022 | 155.35 Mn |
| Mar 31, 2022 | 143.42 Mn |
| Dec 31, 2021 | 135.13 Mn |
| Sep 30, 2021 | 148.94 Mn |
| Jun 30, 2021 | 125.05 Mn |
| Mar 31, 2021 | 122.14 Mn |